169 related articles for article (PubMed ID: 23469069)
1. In silico structural and functional characterization of the RSUME splice variants.
Gerez J; Fuertes M; Tedesco L; Silberstein S; Sevlever G; Paez-Pereda M; Holsboer F; Turjanski AG; Arzt E
PLoS One; 2013; 8(2):e57795. PubMed ID: 23469069
[TBL] [Abstract][Full Text] [Related]
2. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia.
Carbia-Nagashima A; Gerez J; Perez-Castro C; Paez-Pereda M; Silberstein S; Stalla GK; Holsboer F; Arzt E
Cell; 2007 Oct; 131(2):309-23. PubMed ID: 17956732
[TBL] [Abstract][Full Text] [Related]
3. Role of RSUME in inflammation and cancer.
Antico Arciuch VG; Tedesco L; Fuertes M; Arzt E
FEBS Lett; 2015 Nov; 589(22):3330-5. PubMed ID: 26297826
[TBL] [Abstract][Full Text] [Related]
4. Impact of RSUME Actions on Biomolecular Modifications in Physio-Pathological Processes.
Fuertes M; Elguero B; Gonilski-Pacin D; Herbstein F; Rosmino J; Ciancio Del Giudice N; Fiz M; Falcucci L; Arzt E
Front Endocrinol (Lausanne); 2022; 13():864780. PubMed ID: 35528020
[TBL] [Abstract][Full Text] [Related]
5. Relationship between RSUME and HIF-1α/VEGF-A with invasion of pituitary adenoma.
He W; Huang L; Shen X; Yang Y; Wang D; Yang Y; Zhu X
Gene; 2017 Mar; 603():54-60. PubMed ID: 27989771
[TBL] [Abstract][Full Text] [Related]
6. RSUME is implicated in HIF-1-induced VEGF-A production in pituitary tumour cells.
Shan B; Gerez J; Haedo M; Fuertes M; Theodoropoulou M; Buchfelder M; Losa M; Stalla GK; Arzt E; Renner U
Endocr Relat Cancer; 2012 Feb; 19(1):13-27. PubMed ID: 22009797
[TBL] [Abstract][Full Text] [Related]
7. RSUME enhances glucocorticoid receptor SUMOylation and transcriptional activity.
Druker J; Liberman AC; Antunica-Noguerol M; Gerez J; Paez-Pereda M; Rein T; Iñiguez-Lluhí JA; Holsboer F; Arzt E
Mol Cell Biol; 2013 Jun; 33(11):2116-27. PubMed ID: 23508108
[TBL] [Abstract][Full Text] [Related]
8. RSUME is implicated in tumorigenesis and metastasis of pancreatic neuroendocrine tumors.
Wu Y; Tedesco L; Lucia K; Schlitter AM; Garcia JM; Esposito I; Auernhammer CJ; Theodoropoulou M; Arzt E; Renner U; Stalla GK
Oncotarget; 2016 Sep; 7(36):57878-57893. PubMed ID: 27506944
[TBL] [Abstract][Full Text] [Related]
9. von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME.
Tedesco L; Elguero B; Pacin DG; Senin S; Pollak C; Garcia Marchiñena PA; Jurado AM; Isola M; Labanca MJ; Palazzo M; Yankilevich P; Fuertes M; Arzt E
Cell Death Dis; 2019 Mar; 10(4):266. PubMed ID: 30890701
[TBL] [Abstract][Full Text] [Related]
10. Protein stabilization by RSUME accounts for PTTG pituitary tumor abundance and oncogenicity.
Fuertes M; Sapochnik M; Tedesco L; Senin S; Attorresi A; Ajler P; Carrizo G; Cervio A; Sevlever G; Bonfiglio JJ; Stalla GK; Arzt E
Endocr Relat Cancer; 2018 Jun; 25(6):665-676. PubMed ID: 29622689
[TBL] [Abstract][Full Text] [Related]
11. Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.
Maroui MA; Kheddache-Atmane S; El Asmi F; Dianoux L; Aubry M; Chelbi-Alix MK
PLoS One; 2012; 7(9):e44949. PubMed ID: 23028697
[TBL] [Abstract][Full Text] [Related]
12. Mass Spectrometry-Based Metabolic Fingerprinting Contributes to Unveil the Role of RSUME in Renal Cell Carcinoma Cell Metabolism.
Martinefski MR; Elguero B; Knott ME; Gonilski D; Tedesco L; Gurevich Messina JM; Pollak C; Arzt E; Monge ME
J Proteome Res; 2021 Jan; 20(1):786-803. PubMed ID: 33124415
[TBL] [Abstract][Full Text] [Related]
13. RSUME inhibits VHL and regulates its tumor suppressor function.
Gerez J; Tedesco L; Bonfiglio JJ; Fuertes M; Barontini M; Silberstein S; Wu Y; Renner U; Páez-Pereda M; Holsboer F; Stalla GK; Arzt E
Oncogene; 2015 Sep; 34(37):4855-66. PubMed ID: 25500545
[TBL] [Abstract][Full Text] [Related]
14. TRAF-3 mRNA splice-deletion variants encode isoforms that induce NF-kappaB activation.
van Eyndhoven WG; Gamper CJ; Cho E; Mackus WJ; Lederman S
Mol Immunol; 1999 Jul; 36(10):647-58. PubMed ID: 10509816
[TBL] [Abstract][Full Text] [Related]
15. A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor-1alpha gene.
Chun YS; Choi E; Kim TY; Kim MS; Park JW
Biochem J; 2002 Feb; 362(Pt 1):71-9. PubMed ID: 11829741
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the transcriptional activation domains of human TEF3-1 (transcription enhancer factor 3 isoform 1).
Qiao C; Jiang Y; Deng C; Huang Z; Teng K; Chen L; Liu X
Arch Biochem Biophys; 2015 Mar; 569():54-61. PubMed ID: 25687649
[TBL] [Abstract][Full Text] [Related]
17. Isoform-specific monobody inhibitors of small ubiquitin-related modifiers engineered using structure-guided library design.
Gilbreth RN; Truong K; Madu I; Koide A; Wojcik JB; Li NS; Piccirilli JA; Chen Y; Koide S
Proc Natl Acad Sci U S A; 2011 May; 108(19):7751-6. PubMed ID: 21518904
[TBL] [Abstract][Full Text] [Related]
18. Sumoylation of internally initiated Sp3 isoforms regulates transcriptional repression via a Trichostatin A-insensitive mechanism.
Spengler ML; Kennett SB; Moorefield KS; Simmons SO; Brattain MG; Horowitz JM
Cell Signal; 2005 Feb; 17(2):153-66. PubMed ID: 15494207
[TBL] [Abstract][Full Text] [Related]
19. Sumoylation inhibits cleavage of Sp1 N-terminal negative regulatory domain and inhibits Sp1-dependent transcription.
Spengler ML; Brattain MG
J Biol Chem; 2006 Mar; 281(9):5567-74. PubMed ID: 16407261
[TBL] [Abstract][Full Text] [Related]
20. Cross Talk in HEK293 Cells Between Nrf2, HIF, and NF-κB Activities upon Challenges with Redox Therapeutics Characterized with Single-Cell Resolution.
Johansson K; Cebula M; Rengby O; Dreij K; Carlström KE; Sigmundsson K; Piehl F; Arnér ES
Antioxid Redox Signal; 2017 Feb; 26(6):229-246. PubMed ID: 26415122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
